MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mineralys Therapeutics Inc (MLYS) is not a strong buy for a beginner, long-term investor at this moment. While analysts have raised price targets and hedge funds are increasing their positions, the company’s financial performance is weak, with declining net income and EPS. Additionally, technical indicators and options data do not strongly support a buy decision. The lack of recent news or significant catalysts further weakens the case for immediate investment.
The MACD is positive but contracting, RSI is neutral at 24.953, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S2: 26.3) in pre-market, suggesting limited upward momentum in the short term.
Hedge funds have significantly increased their buying activity (+516.79% last quarter). Analysts have raised price targets, citing a potential commercialization and development partnership as a major catalyst.
Weak financial performance in Q3 2025, with a net income drop of -34.45% YoY and EPS decline of -53.98% YoY. No significant insider or congressional trading activity. No recent news or event-driven catalysts.
In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$36.93M (-34.45% YoY), and EPS fell to -0.52 (-53.98% YoY). Gross margin was 0%, indicating no profitability.
Analysts are bullish, with Stifel raising the price target to $52 and BofA raising it to $46. Both maintain Buy ratings, citing a strong cash runway into 2027 and potential for a commercialization partnership as key growth drivers.
